Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol
- 1 September 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 29 (9), 815-825
- https://doi.org/10.1097/mnm.0b013e32830439c6
Abstract
Vectorized internal radiation therapy using lipiodol-labelled with iodine-131 (131 I-lipiodol) is an effective treatment for inoperable hepatocellular carcinomas. However, few dosimetric data are available based on this approach. We have developed a dosimetric protocol based on scintiscan imaging and that is designed to calculate the tumoural absorbed dose during the treatment of hepatocarcinoma by 131 I-lipiodol.This concept was developed on a gamma-camera coupled to a computed tomography scanner. It integrates corrections for attenuation phenomena, scattering and dead time. The tumoural absorbed dose calculation was carried out according to the Medical Internal Radiation Dose Committee formalism. This protocol was applied to a series of 41 patients in the framework of a retrospective study.The mean tumoural absorbed dose with the first treatment is 248 Gy (+/-176), as opposed to 152 Gy (+/-122) during the second. We highlighted a correlation between the tumoural absorbed dose, calculated in tomographic mode, and the morphological response to the first treatment (P=0.0071). Moreover, a tumoural absorbed dose of 280 Gy seems to be an effective absorbed dose threshold in our population. Above this absorbed dose, 84% of the patients are responders after the first treatment, whereas no responses are recorded below this threshold.These results are promising because, for the first time, they allow us to predict the effectiveness of a treatment by 131 I-lipiodol. They are required to be validated on a broader exploratory trial, including a dosimetric study of the critical organs, so an individualized dosimetry can be defined for each patient.Keywords
This publication has 30 references indexed in Scilit:
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Epidemiology of Primary Liver CancerSeminars in Liver Disease, 1999
- Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian ExperienceCancer, 1995
- A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 1995
- Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year Study of 127 French PatientsCancer, 1994
- Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.Gut, 1993
- A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaJournal of Hepatology, 1990
- Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases.Radiology, 1988
- Treatment of Hepatocellular Carcinoma by Transarterial Injection of Anticancer Agents in Iodized Oil Suspension or of Radioactive Iodized Oil SolutionActa Radiologica. Diagnosis, 1986